key: cord-0814170-dgncrdst
authors: Ateş, İhsan; Erden, Abdulsamet; Güven, Serdar Can; Gürler, Elif Kübra; Çağlayan, Adem; Güçbey, Özge; Apaydın, Hakan; Şahiner, Enes Seyda; Küçük, Hamit; Varan, Özkan; Omma, Ahmet; Küçükşahin, Orhan
title: SHOULD TIMING BE CONSIDERED BEFORE ABANDONING CONVALESCENT PLASMA IN COVID-19? RESULTS FROM THE TURKISH EXPERIENCE
date: 2021-08-10
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2021.103238
sha: fa41ae823a68b3490f4771b7717847f41919de0c
doc_id: 814170
cord_uid: dgncrdst

INTRODUCTIONS: Results with convalescent plasma therapy in coronavirus disease 2019 (COVID-19) have been contradictory. Timing seems to be an important factor for COVID-19 convalescent plasma(CCP) to be effective. Aim of this study is to compare disease outcomes in hospitalized COVID-19 patients who were treated with CCP within first three or seven days of symptoms to patients with symptoms longer than seven days. MATERIAL AND METHODS: A multicenter retrospective study was conducted to evaluate disease outcomes in hospitalized COVID-19 patients who received CCP in addition to standard of care (SOC) approach. Patients were subgrouped according to time of CCP administration; within three days of symptoms, seven days of symptoms and after seven days of symptoms. A control group was formed from age, gender and comorbidity matched hospitalized patients who received SOC treatments without CCP. Length of hospital stay, rates of anti-inflammatory treatment initiation, intensive care unit (ICU) admission and mortality was set as outcome measures. RESULTS: A total of 223 patients were enrolled in this study, 113 patients received CCP (38 within three days, 63 within seven days, 50 after seven days of symptom onset). Rate of anti-inflammatory treatment initiation was significantly lower (38.1% vs 62.7%, p = 0.002, relative risk, 0.60,73; 95% confidence interval [CI], 0.42 to 0.85) and length of hospital stay was significantly shorter (median(IQR) 8(4) days vs 9.5(5.25) days, p = 0.0025) in patients who received CCP within seven days of symptom onset when compared to SOC group. CONCLUSION: CCP therapy may provide better outcomes when applied within seven days of symptoms.

Convalescent plasma therapy is collection and transfusion of plasma from those who have recovered from a given infection, in this case coronavirus disease 2019 (COVID-19) [1] [2] [3] . In addition to protective effects of neutralizing antibodies (NAbs), COVID-19 convalescent plasma (CCP) therapy also have anti-inflammatory and immunomodulatory activity, limiting immune complex formation and complement cascade activation [4] .

Nevertheless, enhancement of viral clearance is the foremost effect expected by CCP therapy, therefore administration in early stages of the infection with high viral load and insufficient endogenous immunoglobulin response hypothetically may be more convenient [5, 6] .

Contradictory results with CCP therapy have previously been reported [7] [8] [9] . In their randomized controlled study, Simonovich et al. [7] , did not observe any significant benefit with CCP therapy in COVID-19 patients with mean symptom duration of eight days. On the other hand, Libster et al. [10] demonstrated that early and high-dose administration of CCP therapy reduced progression to severe respiratory failure, even in elderly patients, a patient group considered to be prone to have worse outcomes.

Timing seems to be an important factor to obtain utmost effects from CCP therapy. To further elucidate this issue, in our retrospective cohort study, we aimed to compare disease outcomes in hospitalized COVID-19 patients who were treated with CCP within first three or seven days of symptoms to patients with symptoms longer than seven days.

In this multi-center study, data of hospitalized COVID-19 patients who received CCP therapy in addition to standard of care (SOC) approach from Ankara City Hospital, Internal IgG) titer is > 1.1 in these plasma samples. Each patient receives CCP harvested from a single donor, pooling from multiple donors is not applied. CCP treatment was administered to patients in our study in accordance with these national regulations.

SOC approach comprised oxygen support, hydroxychloroquine, favipiravir, low molecular weight heparin, antiaggregants and additional anti-inflammatory treatment (tocilizumab, anakinra, systemic steroids) when indicated in accordance with COVID-19 guidelines of the Turkish Ministry of Health [11] . Likewise, indications for hospitalization, J o u r n a l P r e -p r o o f CCP therapy administration, intubation and discharge were also set in accordance with Turkish Ministry of Health guidelines [1, 11] .

Data regarding demographics, comorbidities, COVID-19 related symptoms, treatment agents for COVID-19, length of hospital stay, presence of anti-inflammatory treatment initiation, ICU admission and death were recorded in all subjects using a standardized casereport form. All data were checked by 2 physicians (OG and AC), and then a third researcher (EKG) determined any differences in interpretation between the 2 primary reviewers.

CCP receivers were evaluated as a single population, additionally patients who received CCP subgrouped into three according to symptom duration at the time of CCP administration: Patients with symptom duration shorter than seven days, patients with symptom duration shorter than three days and patients with symptoms longer than seven days.

Outcomes in all CCP recipients and in subgroups were compared with outcomes in SOC group with pairwise comparisons. Outcomes in CCP recipients within seven days of symptoms were also compared to those in CCP recipients after seven days. J o u r n a l P r e -p r o o f All procedures in this study were approved by Ankara City Hospital Ethics Committee and were therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

A total of 223 patients were enrolled in this study: 113 patients with administration of CCP and 110 patients with SOC. Demographics, comorbidities and COVID-19 symptoms are presented in Table 1 . No significant differences were observed in age, gender and comorbidities. None of the patients had been recorded to have any adverse reactions with CCP therapy. Median (IQR) days from symptom onset to initiation of SOC treatment was 2(3) in SOC alone patients and 2(2) in all CCP patients.

Outcomes of patients are presented in Table 2 . No significant differences were observed in length of hospital stay and rates of anti-inflammatory treatment need, ICU admission and mortality between patients who received CCP therapy and who did not.

Among patients who received CCP therapy, 55.7% received in first seven days of symptoms while 44.3% received after seven days. Need to anti-inflammatory treatment rate was significantly lower (38.1% vs 62.7%, p=0.002, relative risk, 0.60,73; 95% confidence interval

[CI], 0.42 to 0.85) and length of hospital stay was significantly shorter (median (IQR) 8 (4) days vs 9.5 (5.25) days, p=0.0025) in patients who received CCP within seven days when compared to SOC group. Rates of anti-inflammatory treatment administration (38.1% vs 94%, p<0.001) and ICU admission (6.3% vs 28%, p=0.002) were also significantly lower in patients who received CCP within first seven days of symptoms when compared to patients who received after seven days. Likewise, need to anti-inflammatory treatment rate (28.9% vs 62.7%, p<0.0001; 2.6%) and length of hospital stay (median (IQR) days, 7 (1.5) vs 9.5 (5.25), J o u r n a l P r e -p r o o f p=0.003) were significantly lower in patients who received CCP within first three days when compared to SOC group.

The relative risk reduction for ICU admission with CCP therapy within first seven days of symptoms when compared to SOC was 39.27% and the number needed to treat to avert an ICU admission was 4 (95% CI, 3 to 11). The relative risk reduction with CCP therapy within first three days of symptoms when compared to SOC was 53.85% and the number needed to treat to avert an intensive care unit admission was 3 (95% CI, 2 to 6).

Our results demonstrated reduced rates of ICU admission and anti-inflammatory therapy administration with CCP therapy in patients who received CCP within seven days of symptom onset. Furthermore, hospital stay shortened when therapy induced within three or seven days of symptom onset when compared to SOC.

COVID-19 pandemic on goes without any curative therapy. Since need for hospitalization and ICU admission is a prominent concern, early interventions to prevent worse outcomes come forward.

CCP is obtained from recovered COVID-19 patients who developed humoral immunity, containing neutralizing antibodies for SARS CoV-2 capable of pathogen clearance from peripheral circulation and pulmonary tissues [12] . Potential mechanisms of action for CCP are virus neutralization, antibody dependent virolysis, antibody dependent antigen presentation, antibody dependent cellular toxicity and complement activation [13] .

Promising effects of convalescent plasma were demonstrated in SARS CoV-1 when patients received therapy within 14 days of symptom onset [14] . CCP also reported to be J o u r n a l P r e -p r o o f advantageous for reducing mortality in COVID-19 particularly when administered within seven days of symptom onset [6, 15] . Similarly, American Association of Blood Banks (AABB) recommends administration of CCP as close to symptom onset as possible [16] . On the other hand, Simonovich et al. did not report any beneficial effect with CCP in a subgroup of patients who received the therapy within 72 hours, questioning the role of CCP in management of COVID-19 [7] . However, Libster et al. [10] demonstrated prominent effects in mildly affected elderly patients with early high dose administration of CCP. The relative risk reduction with convalescent plasma was 48%, and the number needed to treat to avert an episode of severe respiratory disease was 7 (95% CI, 4 to 50) [10] . A retrospective cohort study based on the United States national registry revealed that the unadjusted mortality within 30 days after transfusion was reduced in patients who received CCP within 3 days after diagnosis of COVID-19 (point estimate, 22.2%; 95% CI, 19.9 to 24.8) in comparison to those who received CCP four or more days after the diagnosis (point estimate, 29.5%; 95% CI, 27.6 to 31.6) [9] . In our study, the relative risk reduction for ICU admission was 39.27% when CCP administered within seven days of symptom onset and was 53.85% when treatment [18, 20] . Nevertheless, Libster et al. reported no side effects even in elderly patients [10] . Likewise, none were observed in our study. Since these adverse events have not been observed to be increased following CCP transfusion, CCP seems to confer similar risk to transfusion of non-immune plasma.

Retrospective nature of the study, small sample size, lack of randomization and propensity score matching were major limitations for our study. Even so baseline demographics and frequency of comorbid diseases were similar between CCP and SOC groups. Other limitations were lack of categorization for signal-to-cut off ratios for anti-SARS-CoV-2 IgG antibody levels in CCP solutions and lack of evaluation of symptom severity. Timing of symptom onset is a crucial point in CCP therapy. However, symptom perception may vary from patient to patient which may have been affected timing of CCP administration.

In conclusion, as an overall safe treatment approach, CCP therapy particularly with early administration may provide better outcomes. Since COVID-19 is yet to have a proven curative therapy, CCP may be considered as an effective adjuvant agent in management. 

Adem Çağlayan: Investigation. Özge Güçbey: Investigation Hakan Apaydın: Investigation. Enes Seyda Şahiner: Investigation. Hamit Küçük: Conceptualization, Investigation. Özkan Varan: Conceptualization, Investigation. Ahmet Omma

Project administration, Supervision. Orhan Küçükşahin: Conceptualization, Methodology, Project administration, Supervision REFERENCES

Ministry. TH. Covid-19 Immune (Convalescent) Plasma Supply And Clinical Use Guidelines

Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019

Guidance for the procurement of COVID-19

convalescent plasma: differences between high-and low-middle-income countries

Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Use of convalescent plasma in hospitalized patients with COVID-19: case series

A randomized trial of convalescent plasma in Covid-19 severe pneumonia

Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

SARS-CoV-2 INFECTION) GUIDE Study of Scientific Board

Convalescent plasma: new evidence for an old therapeutic tool?

Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis

Use of convalescent plasma therapy in SARS patients in Hong Kong

Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion

COVID-19 convalescent plasma: Interim recommendations from the AABB. Transfusion

Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients

Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: a case report

Plasma Transfusion

Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic

This research did not receive any grant

All authors substantially contributed to study design and acquisition, analysis and interpretation of the data. All authors revised the final version of the work and approved for publication in agreement on all aspects of the study.